Real estate activist Jonathan Litt discusses concerns that REIT boards often identify distorted peer groups to justify problematic executive pay, as well as why specific directors at 15 REITs should face vote-no campaigns.

Gibson Dunn M&A partner Brian Scrivani talks about how he handles the stress of legal practice and the importance of maintaining a life outside of work, as well as how he thought about changing law firms. 

Cheryl Reicin, the co-chair of the life sciences group at Mintz, discusses how she became a biotech lawyer and why observing the Sabbath has been good for her as a lawyer. 

Andrew Shapiro, who ran an activist fund for 32 years, discusses how one campaign helped form his investment vehicle and talks about good and bad investor communication policies.

Brian Breheny, the former chief of the SEC's M&A division, discusses expected changes to regulations affecting activist investors, including why he thinks the nation's securities regulator can eliminate activist shareholder proposals.

Rick Giovannelli, the incoming co-chair of the management committee at K&L Gates, discusses the growth of private equity in Charlotte, N.C., over the course of his career and how his firm teaches lawyers to mentor and train the next generation. 

HCI Equity co-founder and chief investment officer Doug McCormick discusses the firm's approach to buy-and-build strategies in large, fragmented and stable markets as well as navigating the challenging M&A environment in 2025. 

Rob Kindler, an M&A partner at Paul Weiss, discusses his career as an M&A lawyer and banker, doing deals at Morgan Stanley and the importance of lifelong connectivity. 

When corporations install anti-activist poison pills they are less likely to implement new share buybacks and their operationally-focused capital expenditures tend to be higher, UC Berkeley School of Law professor Ofer Eldar explains.

Joele Frank discusses how she came to public relations and her approach to growing her own firm.